Cathie Wood's Ark Invest unveiled its latest trading activity on September 22, making substantial purchases of Rocket Lab while trimming its stake in Alphabet, alongside further adjustments within its biotech-focused funds. The most significant transaction of the day centered on Rocket Lab, with Ark's Innovation ETF, Autonomous Technology & Robotics ETF, and Space Exploration & Innovation ETF collectively acquiring 359,612 shares of the company, valued at approximately $25.13 million.
Rocket Lab, a provider of rocket launches, satellites, and other space systems services, emerged as the primary accumulation target for Ark on that session. This move underscores the firm's continued expansion of its allocation toward the commercial space sector.
Alphabet (GOOGL) Sell-Off Exceeds $5.8 Million
In contrast to the sizable Rocket Lab purchase, Ark continued to reduce its position in Alphabet during the same trading day. Through its ARKQ and ARKX funds, the firm offloaded a combined 16,422 shares of the tech giant, generating roughly $5.83 million in proceeds. In terms of transaction scale, Alphabet ranked among the more significant divestments for Ark that day. However, this specific trade likely mirrors routine portfolio rebalancing rather than a definitive shift in Ark's long-term investment outlook on the company.
Biotech Sector Sees Continued Rotational Shifts
Beyond technology and space-related assets, Ark executed numerous biotech trades on September 22, involving both buys and sells within this segment. On the divestment side, the Genomic Revolution ETF sold 21,335 shares of Twist Bioscience, valued at roughly $3.54 million. The same fund also reduced its holdings in 10x Genomics, selling 49,651 shares for approximately $3.93 million.
Concurrently, the firm raised its stakes in several genomics and precision medicine companies. Ark's ARKG fund purchased 88,323 shares of Scribe Therapeutics, worth about $2.48 million, extending a pattern of recent accumulation in that name. Additional acquisitions included 12,583 shares of Veracyte for around $522,000 and 9,519 shares of Beam Therapeutics for nearly $240,000. These moves indicate that Ark's biotech adjustments were not uniform across the board but involved a strategic reallocation of capital between different holdings.
Everpure Stake Continues to Shrink
Furthermore, Ark reduced its position in Everpure through the Next Generation Internet ETF, selling 19,139 shares for approximately $2.18 million on the same day. This transaction follows a similar reduction in the prior session, signaling a consistent, ongoing trend of lowering exposure to that particular asset.
Overall, Ark's trading on September 22 clustered around three focal points: heavy accumulation in Rocket Lab, a reduction of its Alphabet holding, and intra-sector restructuring within the biotech arena. Notably, the roughly $25.13 million investment in Rocket Lab significantly surpassed the value of any other single trade that day, marking it as the most prominent portfolio adjustment.
Comments